Jennifer R. Brown, MD, PhD, on BTK Inhibitors: Zanubrutinib, Ibrutinib, Acalabrutinib in CLL/SLL

Posted: Monday, September 23, 2019

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses trials studying the potential risks and benefits of zanubrutinib, ibrutinib, and acalabrutinib in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.